Literature DB >> 21941374

Interstitial Lung Disease in Idiopathic Inflammatory Myopathy.

Lesley Ann Saketkoo1, Dana P Ascherman, Vincent Cottin, Lisa Christopher-Stine, Sonye K Danoff, Chester V Oddis.   

Abstract

The lung is one of the most common extra-muscular targets in idiopathic inflammatory myopathies (IIM) and interstitial lung disease (ILD) is a prevalent and often devastating manifestation of IIM. IIM-associated ILD (IIM-ILD) contributes to nearly 80% of the mortality in IIM with a reported prevalence of 65% of newly diagnosed IIM cases. Although ILD frequently accompanies clinical and laboratory findings of myositis, overt signs of muscle disease may be absent in the setting of significant lung disease. Understanding the varied scope of presentation of these diseases is essential to providing optimal patient care. This review will provide an in depth examination of ILD in IIM both from a rheumatologic and pulmonary perspective and will discuss the scope of disease, presenting features, genetic associations, pathogenesis, diagnosis, radiographic and histopathologic findings, along with biomarker assessment and a rationale for therapeutic intervention.

Entities:  

Year:  2010        PMID: 21941374      PMCID: PMC3092635          DOI: 10.2174/157339710791330740

Source DB:  PubMed          Journal:  Curr Rheumatol Rev        ISSN: 1573-3971


  109 in total

Review 1.  Pulmonary complications of connective tissue diseases.

Authors:  Felix Woodhead; Athol U Wells; Sujal R Desai
Journal:  Clin Chest Med       Date:  2008-03       Impact factor: 2.878

2.  Long-term efficacy of mycophenolate mofetil in a case of refractory antisynthetase syndrome.

Authors:  Baptiste Hervier; Agathe Masseau; Jean-Marie Mussini; Marie Audrain; Mohamed A Hamidou
Journal:  Joint Bone Spine       Date:  2009-05-21       Impact factor: 4.929

3.  Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients.

Authors:  Patrick Cherin; S Pelletier; A Teixeira; P Laforet; T Genereau; A Simon; T Maisonobe; B Eymard; S Herson
Journal:  Arthritis Rheum       Date:  2002-02

4.  Increased levels of KL-6 and subsequent mortality in patients with interstitial lung diseases.

Authors:  H Satoh; K Kurishima; H Ishikawa; M Ohtsuka
Journal:  J Intern Med       Date:  2006-11       Impact factor: 8.989

5.  Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis.

Authors:  Hideto Kameda; Hayato Nagasawa; Hiroe Ogawa; Naoya Sekiguchi; Hirofumi Takei; Michihide Tokuhira; Koichi Amano; Tsutomu Takeuchi
Journal:  J Rheumatol       Date:  2005-09       Impact factor: 4.666

6.  Interstitial lung disease associated with anti-PM/Scl or anti-aminoacyl-tRNA synthetase autoantibodies: a similar condition?

Authors:  Jean-Christophe Lega; Vincent Cottin; Nicole Fabien; Françoise Thivolet-Béjui; Jean-François Cordier
Journal:  J Rheumatol       Date:  2010-03-15       Impact factor: 4.666

7.  Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis.

Authors:  R W Tobin; C E Pope; C A Pellegrini; M J Emond; J Sillery; G Raghu
Journal:  Am J Respir Crit Care Med       Date:  1998-12       Impact factor: 21.405

8.  Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis/dermatomyositis.

Authors:  Yuzo Suzuki; Hiroshi Hayakawa; Seiichi Miwa; Masahiro Shirai; Masato Fujii; Hitoshi Gemma; Takafumi Suda; Kingo Chida
Journal:  Lung       Date:  2009-04-22       Impact factor: 2.584

Review 9.  A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis siné myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies.

Authors:  Pedram Gerami; Jennifer M Schope; Lauren McDonald; Hobart W Walling; Richard D Sontheimer
Journal:  J Am Acad Dermatol       Date:  2006-01-23       Impact factor: 11.527

10.  Interstitial lung disease in polymyositis and dermatomyositis.

Authors:  I Marie; E Hachulla; P Chérin; S Dominique; P-Y Hatron; M-F Hellot; B Devulder; S Herson; H Levesque; H Courtois
Journal:  Arthritis Rheum       Date:  2002-12-15
View more
  23 in total

1.  The ILD-GAP risk prediction model performs poorly in myositis-associated interstitial lung disease.

Authors:  Rebeccah M Brusca; Iago Pinal-Fernandez; Kevin Psoter; Julie J Paik; Jemima Albayda; Christopher Mecoli; Eleni Tiniakou; Andrew L Mammen; Lisa Christopher-Stine; Sonye Danoff; Cheilonda Johnson
Journal:  Respir Med       Date:  2019-02-21       Impact factor: 3.415

Review 2.  Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment.

Authors:  Tsuneyo Mimori; Ran Nakashima; Yuji Hosono
Journal:  Curr Rheumatol Rep       Date:  2012-06       Impact factor: 4.592

3.  Inflammatory myopathy and interstitial lung disease in antisynthetase syndrome with PL-7 antibody.

Authors:  Sílvia Aguiar Rosa; Paulo Barreto; Marisa Mariano; Isabel Baptista
Journal:  BMJ Case Rep       Date:  2014-10-07

Review 4.  Clinical and radiological features of lung disorders related to connective-tissue diseases: a pictorial essay.

Authors:  Stefano Palmucci; Federica Galioto; Giulia Fazio; Agata Ferlito; Giovanna Cancemi; Alessia Di Mari; Gianluca Sambataro; Domenico Sambataro; Giovanni Zanframundo; Letizia Antonella Mauro; Pietro Valerio Foti; Carlo Vancheri; Antonio Basile
Journal:  Insights Imaging       Date:  2022-06-29

Review 5.  Management of connective tissue diseases associated interstitial lung disease: a review of the published literature.

Authors:  Beth Wallace; Dharshan Vummidi; Dinesh Khanna
Journal:  Curr Opin Rheumatol       Date:  2016-05       Impact factor: 5.006

Review 6.  A roadmap to promote clinical and translational research in rheumatoid arthritis-associated interstitial lung disease.

Authors:  Tracy J Doyle; Joyce S Lee; Paul F Dellaripa; James A Lederer; Eric L Matteson; Aryeh Fischer; Dana P Ascherman; Marilyn K Glassberg; Jay H Ryu; Sonye K Danoff; Kevin K Brown; Harold R Collard; Ivan O Rosas
Journal:  Chest       Date:  2014-03-01       Impact factor: 9.410

7.  The 2011 ACR meeting: what's new in the Windy City.

Authors:  David S Pisetsky
Journal:  Arthritis Res Ther       Date:  2011-12-21       Impact factor: 5.156

8.  Anti-MDA5 antibody is associated with A/SIP and decreased T cells in peripheral blood and predicts poor prognosis of ILD in Chinese patients with dermatomyositis.

Authors:  Fang Chen; Dongxue Wang; Xiaoming Shu; Ran Nakashima; Guochun Wang
Journal:  Rheumatol Int       Date:  2011-12-25       Impact factor: 3.580

9.  Serum progranulin levels are elevated in dermatomyositis patients with acute interstitial lung disease, predicting prognosis.

Authors:  Atsushi Tanaka; Hiroshi Tsukamoto; Hiroki Mitoma; Chikako Kiyohara; Naoyasu Ueda; Masahiro Ayano; Shun-ichiro Ohta; Yasutaka Kimoto; Mitsuteru Akahoshi; Yojiro Arinobu; Hiroaki Niiro; Yoshifumi Tada; Takahiko Horiuchi; Koichi Akashi
Journal:  Arthritis Res Ther       Date:  2015-02-10       Impact factor: 5.156

10.  Limitations to the 6-minute walk test in dermatomyositis with interstitial lung disease in comparison with idiopathic interstitial pneumonia.

Authors:  Fujiko Someya; Naoki Mugii
Journal:  Clin Med Insights Circ Respir Pulm Med       Date:  2013-01-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.